SRW Ndo1 Equilibrium Blood Sugar Support Supplement for Healthy Glucose Balance

Product Overview

SRW Ndo¹ Equilibrium targets post-meal blood glucose management through three complementary botanical mechanisms. Mulberry leaf extract standardised to 5% 1-deoxynojirimycin (DNJ) — a naturally occurring iminosugar — competitively inhibits intestinal alpha-glucosidase enzymes that break down complex carbohydrates into glucose, thereby slowing postprandial glucose absorption. Eriomin™, a standardised lemon flavonoid extract (Citrus limon, 70% eriocitrin), has demonstrated beneficial effects on insulin sensitivity and metabolic markers in peer-reviewed human clinical trials, including a randomised controlled trial published in Phytotherapy Research. Dahlia4™ provides dahlia-derived inulin-type fructooligosaccharides that support glycaemic response modulation and prebiotic gut microbiome effects relevant to metabolic health.

The Ndo¹ formulation was designed by SRW Laboratories as part of its systems-biology approach to healthy ageing, addressing the progressive decline in glucose tolerance and insulin sensitivity that accompanies ageing — a trajectory associated with increased risk of metabolic syndrome, type 2 diabetes, and cardiovascular disease per the WHO and International Diabetes Federation epidemiological data relevant to Singapore's population.

Supplement Facts

Clinical Applications

• Postprandial glucose management: Mulberry leaf DNJ inhibits intestinal alpha-glucosidase (the enzyme that cleaves disaccharides into monosaccharides), reducing and delaying peak glucose absorption after carbohydrate-rich meals — a mechanism shared by the pharmaceutical drug acarbose but through a natural botanical source.
• Insulin sensitivity support: Eriomin™ (eriocitrin) has been evaluated in randomised controlled trials demonstrating improvements in HOMA-IR (homeostatic model assessment of insulin resistance) and fasting insulin in adults with pre-metabolic syndrome criteria.
• Prebiotic gut health: Dahlia4™ inulin-type fructooligosaccharides selectively promote growth of beneficial Bifidobacterium and Lactobacillus species in the gut, supporting the gut-metabolic axis relevant to insulin sensitivity and reducing systemic endotoxaemia from dysbiotic gram-negative bacteria.
• Healthy ageing glucose homeostasis: Age-related decline in beta-cell function and insulin receptor sensitivity begins in the fourth decade of life; Ndo¹ provides botanical support for maintaining glucose homeostasis during this trajectory, complementary to dietary carbohydrate management and regular aerobic exercise.
• Metabolic syndrome prevention support: For Singapore adults meeting 2–3 criteria of metabolic syndrome (abdominal obesity, elevated fasting glucose, dyslipidaemia) who are not yet on pharmacological intervention, Ndo¹ provides clinically-grounded supplement support under physician monitoring.
• Complementary to dietary carbohydrate management: Suitable alongside low-GI dietary patterns per Singapore HPB dietary guidelines; not a replacement for lifestyle intervention or prescription antidiabetic medications in diagnosed T2DM.

Frequently Asked Questions

Q: How does 1-deoxynojirimycin (DNJ) in Mulberry leaf differ from pharmaceutical alpha-glucosidase inhibitors like acarbose?
A: Both DNJ and acarbose inhibit intestinal alpha-glucosidase, reducing postprandial glucose peaks. Acarbose is a prescription pharmaceutical with documented gastrointestinal side effects (flatulence, bloating) due to its potent inhibition. Mulberry leaf DNJ provides gentler, dose-dependent inhibition at supplement concentrations, with a generally milder GI side-effect profile. Ndo¹ is a health supplement — not a pharmaceutical antidiabetic — and is not intended to replace medications prescribed for type 2 diabetes.

Q: When during the day should SRW Ndo¹ be taken for maximum effect?
A: Given the alpha-glucosidase inhibitory mechanism of Mulberry leaf DNJ, taking Ndo¹ immediately before or with the largest carbohydrate-containing meal of the day is clinically logical to coincide with peak intestinal glucosidase activity. SRW Laboratories recommends 2 capsules daily with food; consult a healthcare practitioner for personalised timing based on meal composition and any concurrent medications.

Q: Can SRW Ndo¹ be taken by individuals already prescribed metformin or other antidiabetic medications?
A: Individuals on antidiabetic medications (metformin, SGLT-2 inhibitors, sulfonylureas, GLP-1 agonists, or insulin) should consult their physician before adding Ndo¹. Alpha-glucosidase inhibition from DNJ may have additive glucose-lowering effects that require adjustment of medication dosing. EMIS Asia recommends that any person with diagnosed diabetes or impaired fasting glucose use this supplement only under medical supervision.

Q: Is SRW Ndo¹ suitable for long-term daily use?
A: SRW Ndo¹ is formulated for continuous daily use as part of a metabolic health maintenance regimen. The botanical ingredients — dahlia inulin-type fructooligosaccharides, eriocitrin, and mulberry DNJ — have been evaluated in longer-term safety studies and human trials without clinically significant adverse effects. As with all health supplements, annual review with a healthcare practitioner is recommended, particularly for individuals with hepatic or renal impairment.

Q: Is SRW Ndo¹ available for Singapore healthcare institutions or corporate wellness programmes?
A: Yes. EMIS Asia supplies SRW Ndo¹ to Singapore integrative medicine clinics, preventive health programmes, and corporate wellness managers. As a health supplement under the Singapore HSA Health Products Act, Ndo¹ does not require medical device registration. Institutional pricing and standing order arrangements are available for eligible purchasers.